Yahoo•2026-04-20
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesTRVI — Trevi Therapeutics Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
$14.62+14.49%Market cap1.47B
- Latest Close
- $14.62
- 30-Day Move
- +14.5%
- Market Cap
- $1.5B
- Shares Outstanding
- 128,230,000
- P/B Ratio
- 8.76
- ROE
- -23.3%
Analyst consensus: Buy · 18 analysts
NASDAQ:TRVIPharmaceuticals / PharmaceuticalsDelayed public snapshot
Trevi Therapeutics Inc
A read-only Alphactor snapshot forTrevi Therapeutics Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$14.62
30-Day Move
+14.5%
Market Cap
$1.5B
Shares Outstanding
128,230,000
P/B Ratio
8.76
ROE
-23.3%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$14.62
+14.5%last 90 delayed daily bars
Market cap$1.5B
90D High
$16.12
90D Low
$9.82
Avg Volume
1,504,154
What stands out
TRVI is up 14.5% over the last 30 trading days shown on this page.
Latest operating income is $-10M, which helps anchor the headline ratios with an actual earnings figure.
Fundamentals snapshot
Latest Close
$14.62
30-Day Move
+14.5%
Market Cap
$1.5B
Shares Outstanding
128,230,000
P/B Ratio
8.76
ROE
-23.3%
ROA
-22.1%
Debt / Equity
0
Current Ratio
19.66
Latest Revenue
$0
Financial statement snapshot
Revenue
$0
Gross Profit
--
Operating Income
$-10M
Net Income
$-8M
Gross Margin
--
Net Margin
--
Current Ratio
19.66
Debt / Equity
0.00
Quality snapshot
Altman Z
84.35
Safe
Piotroski
4
Moderate (4-6)
Cash Conversion
0.98x
Rule of 40
--
Insufficient data
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-30M | $-29M | $-28M |
| 2023-12-31 | $0 | $-34M | $-29M | $-32M |
| 2024-12-31 | $0 | $-52M | $-48M | $-38M |
| 2025-12-31 | $0 | $-49M | $-43M | $-42M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Finnhub•2026-04-20
Trevi Therapeutics announces closing of $173 million underwritten offeringSeekingAlpha•2026-04-17
Trevi Therapeutics: Late-Stage Transition Meets Execution RiskYahoo•2026-04-17
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday as Investors Take Positions Amid Corporate EarningsBenzinga•2026-04-17
What's Going On With Trevi Therapeutics Stock?After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3,424,263 | 0.03% | 2025-12-31 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 2,622,306 | 0.02% | 2025-12-31 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 2,288,485 | 0.02% | 2026-02-28 |
| iShares Trust-iShares Russell 2000 ETF | 2,217,467 | 0.02% | 2026-02-28 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1,290,330 | 0.01% | 2026-01-31 |
| AB CAP FUND, INC.-AB Small Cap Growth Portfolio | 1,287,509 | 0.01% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1,126,019 | 0.01% | 2025-12-31 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1,000,000 | 0.01% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Two Sigma Advisers
Filed 2025-08-14
--
--
FMR LLC (Fidelity)
Filed 2026-02-17
$81M
+97.0%
Vanguard Group
Filed 2026-01-29
$81M
+10.4%
Marshall Wace
Filed 2026-02-13
$57M
--
Geode Capital Management
Filed 2026-02-09
$30M
+8.6%
Goldman Sachs
Filed 2026-02-10
$13M
+34.2%
Charles Schwab
Filed 2026-02-13
$10M
+3.8%
Analyst consensus?
Rating(?)
4.28
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
18
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.